

SA2631 - Pembrolizumab

MSI-H/dMMR advanced colorectal cancer - Initial application	14
MSI-H/dMMR advanced colorectal cancer - Renewal	15
Urothelial carcinoma - Initial application	15
Urothelial carcinoma - Renewal	15
Breast cancer, advanced - Initial application	12
Breast cancer, advanced - Renewal	13
Head and neck squamous cell carcinoma - Initial application	13
Head and neck squamous cell carcinoma - Renewal	14
Non-small cell lung cancer first line combination therapy - Renewal	11
Non-small cell lung cancer first line monotherapy - Renewal	10
Non-small cell lung cancer first-line combination therapy - Initial application	10
Non-small cell lung cancer first-line monotherapy - Initial application	9
Relapsed/refractory Hodgkin lymphoma - Initial application	16
Relapsed/refractory Hodgkin lymphoma - Renewal	16
Stage III or IV resectable melanoma - neoadjuvant - Initial application	2
Stage III or IV resectable melanoma - neoadjuvant - Renewal	3
Stage III or IV resected melanoma - adjuvant - Initial application	4
Stage III or IV resected melanoma - adjuvant - Renewal	5
Unresectable or metastatic melanoma - Initial application	6
Unresectable or metastatic melanoma, less than 24 months on treatment - Renewal	7
Unresectable or metastatic melanoma, more than 24 months on treatment - Renewal	8

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab

Initial application — stage III or IV resectable melanoma - neoadjuvant

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ The individual has resectable stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note)

and ☐ The individual has not received prior funded systemic treatment in the perioperative setting for their stage IIIB, IIIC, IIID or IV melanoma

and ☐ Treatment must be prior to complete surgical resection

and ☐ Pembrolizumab must be administered as monotherapy

and ☐ The individual has ECOG performance score 0-2

and ☐ Pembrolizumab to be administered at a fixed dose of 200 mg every 3 weeks (or equivalent)

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - continued

Renewal — stage III or IV resectable melanoma - neoadjuvant

Current approval Number (if known):.....

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ The individual has received neoadjuvant treatment with an immune checkpoint inhibitor
and
☐ The individual meets initial application criteria for pembrolizumab for stage III or IV resected melanoma – adjuvant

or

- ☐ The individual has received neoadjuvant and adjuvant treatment with an immune checkpoint inhibitor
and
☐ The individual meets renewal criteria for pembrolizumab for stage III or IV resected melanoma – adjuvant

or

- ☐ The individual has received neoadjuvant and adjuvant treatment with an immune checkpoint inhibitor
and
☐ The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV
and
☐ The individual meets initial application criteria for pembrolizumab for unresectable or metastatic melanoma

or

- ☐ The individual has received neoadjuvant and adjuvant treatment with an immune checkpoint inhibitor
and
☐ The individual has received treatment with an immune checkpoint inhibitor for unresectable or metastatic melanoma
and
☐ The individual meets renewal criteria for pembrolizumab for unresectable or metastatic melanoma

Note:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition
- b) Initiating treatment within 13 weeks of complete surgical resection means either 13 weeks after resection (primary or lymphadenectomy) or 13 weeks prior to the scheduled date of the resection (primary or lymphadenectomy)

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - *continued*

Initial application — stage III or IV resected melanoma - adjuvant

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ The individual has resected stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note a)
- and ☐ Adjuvant treatment with pembrolizumab is required
- and ☐ The individual has not received prior funded systemic treatment in the adjuvant setting for stage IIIB, IIIC, IIID or IV melanoma
- and ☐ Treatment must be in addition to complete surgical resection
- and ☐ Treatment must be initiated within 13 weeks of complete surgical resection, unless delay is necessary due to post-surgery recovery (see note b)
- and ☐ Pembrolizumab must be administered as monotherapy
- and ☐ The individual has ECOG performance score 0-2
- and ☐ Pembrolizumab to be administered at a fixed dose of 200 mg every 3 weeks (or equivalent)

Note:

- a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition
- b) Initiating treatment within 13 weeks of complete surgical resection means 13 weeks after resection (primary or lymphadenectomy)

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - *continued*

Renewal — stage III or IV resected melanoma - adjuvant

Current approval Number (if known):.....

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ No evidence of disease recurrence
and
☐ Pembrolizumab must be administered as monotherapy
and
☐ Pembrolizumab to be administered at a fixed dose of 200 mg every three weeks (or equivalent) for a maximum of 12 months total treatment course, including any systemic neoadjuvant treatment
and
☐ Treatment to be discontinued at signs of disease recurrence or at completion of 12 months total treatment course (equivalent to 18 cycles at a dose of 200 mg every 3 weeks), including any systemic neoadjuvant treatment

or

- ☐ The individual has received adjuvant treatment with an immune checkpoint inhibitor
and
☐ The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV
and
☐ The individual meets initial application criteria for pembrolizumab for unresectable or metastatic melanoma

or

- ☐ The individual has received adjuvant treatment with an immune checkpoint inhibitor
and
☐ The individual has received treatment with an immune checkpoint inhibitor for unresectable or metastatic melanoma
and
☐ The individual meets renewal criteria for pembrolizumab for unresectable or metastatic melanoma

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - *continued*

Initial application — unresectable or metastatic melanoma

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

☐	The individual has metastatic or unresectable melanoma (excluding uveal) stage III or IV		
and	☐	Baseline measurement of overall tumour burden is documented clinically and radiologically	
and	☐	The individual has ECOG performance score of 0-2	
and	☐	The individual has not received funded nivolumab	
or	☐	The individual has received an initial Special Authority approval for nivolumab and has discontinued nivolumab within 12 weeks of starting treatment due to intolerance	
	and	☐	The cancer did not progress while the individual was on nivolumab
and	☐	The individual has been diagnosed in the metastatic or unresectable stage III or IV setting	
or	☐	The individual did not receive treatment in the perioperative setting with a PD-1/PD-L1 inhibitor	
or	☐	The individual received treatment in the perioperative setting with a PD-1/PD-L1 inhibitor	
	and	☐	The individual did not experience disease recurrence while on treatment with that PD-1/PD-L1 inhibitor
	and	☐	The individual did not experience disease recurrence within six months of completing perioperative treatment with a PD-1/PD-L1 inhibitor

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - *continued*

Renewal — unresectable or metastatic melanoma, less than 24 months on treatment

Current approval Number (if known):.....

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ The individual's disease has had a complete response to treatment
or
☐ The individual's disease has had a partial response to treatment
or
☐ The individual has stable disease

and

- ☐ Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

or

- ☐ The individual has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression
and
☐ The individual has signs of disease progression
and
☐ Disease has not progressed during previous treatment with pembrolizumab

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - *continued*

Renewal — unresectable or metastatic melanoma, more than 24 months on treatment

Current approval Number (if known):.....

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

☐	The individual has been on treatment for more than 24 months
and	
☐	The individual's disease has had a complete response to treatment
or	
☐	The individual's disease has had a partial response to treatment
or	
☐	The individual has stable disease
and	
☐	Response to treatment in target lesions has been determined by comparable radiologic or clinical assessment following the most recent treatment period
or	
☐	The individual has previously discontinued treatment with pembrolizumab for reasons other than severe toxicity or disease progression
and	
☐	The individual has signs of disease progression
and	
☐	Disease has not progressed during previous treatment with pembrolizumab

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - *continued*

Initial application — non-small cell lung cancer first-line monotherapy

Applications only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer
and
☐ Patient has not had chemotherapy for their disease in the palliative setting
and
☐ Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC
and
☐ For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR, ROS-1 or ALK tyrosine kinase unless not possible to ascertain
and
☐ Pembrolizumab to be used as monotherapy
and

☐ There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 50% as determined by a validated test unless not possible to ascertain
or

☐ There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 1% as determined by a validated test unless not possible to ascertain
and
☐ Chemotherapy is determined to be not in the best interest of the patient based on clinician assessment
- and
☐ Patient has an ECOG 0-2
and
☐ Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks
and
☐ Baseline measurement of overall tumour burden is documented clinically and radiologically

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - *continued*

Renewal — non-small cell lung cancer first line monotherapy

Current approval Number (if known):.....

Applications only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient's disease has had a complete response to treatment
- or
- ☐ Patient's disease has had a partial response to treatment
- or
- ☐ Patient has stable disease

and

- ☐ Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

and

- ☐ No evidence of disease progression

and

- ☐ The treatment remains clinically appropriate and patient is benefitting from treatment

and

- ☐ Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent)

and

- ☐ Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

Initial application — non-small cell lung cancer first-line combination therapy

Applications only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer
- and
- ☐ The patient has not had chemotherapy for their disease in the palliative setting
- and
- ☐ Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC
- and
- ☐ For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR, ROS-1 or ALK tyrosine kinase unless not possible to ascertain
- and
- ☐ Pembrolizumab to be used in combination with platinum-based chemotherapy
- and
- ☐ Patient has an ECOG 0-2
- and
- ☐ Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks
- and
- ☐ Baseline measurement of overall tumour burden is documented clinically and radiologically

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - continued

Renewal — non-small cell lung cancer first line combination therapy

Current approval Number (if known):.....

Applications only from a medical oncologist or any relevant practitioner on the recommendation of a medical oncologist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient's disease has had a complete response to treatment

or

☐ Patient's disease has had a partial response to treatment

or

☐ Patient has stable disease

and

- ☐ Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period

and

- ☐ No evidence of disease progression

and

- ☐ The treatment remains clinically appropriate and patient is benefitting from treatment

and

- ☐ Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent)

and

- ☐ Treatment with pembrolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - *continued*

Initial application — breast cancer, advanced

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment
- or
- ☐ Patient has recurrent or de novo unresectable, inoperable locally advanced triple-negative breast cancer (that does not express ER, PR or HER2 IHC3+ or ISH+ [including FISH or other technology])

or

☐ Patient has recurrent or de novo metastatic triple-negative breast cancer (that does not express ER, PR or HER2 IHC3+ or ISH+ [including FISH or other technology])
- and
- ☐ Patient is treated with palliative intent
- and
- ☐ Patient's cancer has confirmed PD-L1 Combined Positive Score (CPS) is greater than or equal to 10
- and
- ☐ Patient has received no prior systemic therapy in the palliative setting
- and
- ☐ Patient has an ECOG score of 0–2
- and
- ☐ Pembrolizumab is to be used in combination with chemotherapy
- and
- ☐ Baseline measurement of overall tumour burden is documented clinically and radiologically
- and
- ☐ Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - continued

Renewal — breast cancer, advanced

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient's disease has had a complete response to treatment
or
☐ Patient's disease has had a partial response to treatment
or
☐ Patient has stable disease

and

- ☐ No evidence of disease progression

and

- ☐ Response to treatment in target lesions has been determined by a comparable radiologic assessment following the most recent treatment period

and

- ☐ Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent)

and

- ☐ Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

Initial application — head and neck squamous cell carcinoma

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment

or

- ☐ Patient has recurrent or metastatic head and neck squamous cell carcinoma of mucosal origin (excluding nasopharyngeal carcinoma) that is incurable by local therapies

and

- ☐ Patient has not received prior systemic therapy in the recurrent or metastatic setting

and

- ☐ Patient has a positive PD-L1 combined positive score (CPS) of greater than or equal to 1

and

- ☐ Patient has an ECOG performance score of 0-2

and

- ☐ Pembrolizumab to be used in combination with platinum-based chemotherapy

or

- ☐ Pembrolizumab to be used as monotherapy

and

- ☐ Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable) **PATIENT** NHI: **REFERRER** Reg No:

Reg No: First Names: First Names:

Name: Surname: Surname:

Address: DOB: Address:

..... Address:

.....

Fax Number: Fax Number:

Pembrolizumab - continued

Renewal — head and neck squamous cell carcinoma

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient's disease has had a complete response to treatment
or
☐ Patient's disease has had a partial response to treatment
or
☐ Patient has stable disease

and

- ☐ No evidence of disease progression

and

- ☐ Pembrolizumab is to be used at a maximum dose of 200 mg every three weeks (or equivalent)

and

- ☐ Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

Initial application — MSI-H/dMMR advanced colorectal cancer

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Individual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment

or

- ☐ Individual has deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer
or
☐ Individual has deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) unresectable colorectal cancer

and

- ☐ Individual is treated with palliative intent

and

- ☐ Individual has not previously received funded treatment with pembrolizumab for MSI-H/dMMR advanced colorectal cancer

and

- ☐ Individual has an ECOG performance score of 0-2

and

- ☐ Baseline measurement of overall tumour burden is documented clinically and radiologically

and

- ☐ Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - continued

Renewal — MSI-H/dMMR advanced colorectal cancer

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ No evidence of disease progression
- and
- ☐ Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent)
- and
- ☐ Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

Initial application — Urothelial carcinoma

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment
- or
- ☐ Patient has inoperable locally advanced (T4) or metastatic urothelial carcinoma

and

☐ Patient has an ECOG performance score of 0-2

and

☐ Patient has documented disease progression following treatment with chemotherapy

and

☐ Pembrolizumab to be used as monotherapy at a maximum dose of 200 mg every three weeks (or equivalent) for a maximum of 16 weeks

Renewal — Urothelial carcinoma

Current approval Number (if known):.....

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient's disease has had a complete response to treatment

or

☐ Patient's disease has had a partial response to treatment

or

☐ Patient has stable disease
- and
- ☐ No evidence of disease progression
- and
- ☐ Pembrolizumab to be used at a maximum dose of 200 mg every three weeks (or equivalent)
- and
- ☐ Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
.....	Address:	
.....		
Fax Number:		Fax Number:

Pembrolizumab - *continued*

Initial application — relapsed/refractory Hodgkin lymphoma

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months.

Prerequisites(tick boxes where appropriate)

- ☐ Individual is currently on treatment with pembrolizumab and met all remaining criteria prior to commencing treatment
- or
- ☐ Individual has relapsed/refractory Hodgkin lymphoma after two or more lines of chemotherapy

and

☐ Individual is ineligible for autologous stem cell transplant
- or
- ☐ Individual has relapsed/refractory Hodgkin lymphoma and has previously undergone an autologous stem cell transplant
- and
- ☐ Individual has not previously received funded pembrolizumab for relapsed/refractory Hodgkin lymphoma
- and
- ☐ Pembrolizumab to be administered at doses no greater than 200 mg once every 3 weeks

Renewal — relapsed/refractory Hodgkin lymphoma

Current approval Number (if known):.....

Applications only from a relevant specialist or any relevant practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months.

Prerequisites(tick boxes where appropriate)

- ☐ Patient has received a partial or complete response to pembrolizumab
- and
- ☐ Treatment with pembrolizumab is to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: Date:

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: customerservice@health.govt.nz